Recent Headlines
Within Biopharmaceuticals & Biotherapeutics

Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications

Creative Diagnostics has announced the release of its new line of Azaperone Test Reagents. - October 15, 2023 - Creative Diagnostics

Creative Diagnostics Launches Checkerboard Assay Services

Creative Diagnostics has recently announced the launch of its new Checkerboard Assay services to support researchers. - October 15, 2023 - Creative Diagnostics

NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School

NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the Pepperdine Graziadio Business School's sixth annual Most Fundable Companies® List. NuvOx Therapeutics competed against over 3,000 of early-stage US companies to be named one of 17 companies in total. - October 11, 2023 - NuvOx Therapeutics

Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions

Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions. Researchers can screen a protein of interest against 22 biologically relevant lipids in one assay in a single day at a lower price compared with existing commercial options. - October 04, 2023 - Cayman Chemical Company

NuvOx Closed Oversubscribed Convertible Notes

NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round, raising approximately $7M out of the originally planned $5M. In this raise, NuvOx leverages large angel groups nationwide, and 11 angel groups joined the round. As a result, NuvOx... - September 27, 2023 - NuvOx Therapeutics

National Brain Tumor Society to Launch Campaigns Elevating the Necessity of Clinical Trials and Biomarker Testing Access, Guiding More Informed Treatment Decisions

Joint initiatives aim to help patients and families navigate the era of precision medicine in cancer care. - September 13, 2023 - National Brain Tumor Society

Creative Diagnostics Launches Antimicrobial Synergy Testing Services

Creative Diagnostics has recently launched a series of Antimicrobial Synergy Testing Services to the reserch community. - September 06, 2023 - Creative Diagnostics

Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research

Creative Diagnostics has announced a series of new ELISA Kits to assist researchers in studing the mechanisms of autoimmunity. - September 06, 2023 - Creative Diagnostics

NuvOx Announces Publication of Research Article in Cancer Research Communication

NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications. https://aacrjournals.org/cancerrescommun/article/3/8/1607/728499. Evan Unger, MD, President and CEO of NuvOx,... - September 01, 2023 - NuvOx Therapeutics

Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease

The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023 - Huntington Study Group

Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study

The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), today announces positive topline results from its Virtual Unified Huntington’s Disease Rating Scale®... - August 14, 2023 - Huntington Study Group

Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates

Creative Diagnostics has announced a series of new reagent solutions to assist researchers in the bioanalysis of ADCs. - August 06, 2023 - Creative Diagnostics

Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services

Creative Diagnostics announced the launch of its new Antimicrobial Susceptibility Testing (AST) services. - August 06, 2023 - Creative Diagnostics

Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD

HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023 - Huntington Study Group

Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics

Cayman and Navinci have partnered to bring next-generation proximity ligation-based solutions for spatial proteomics to US and Canada-based researchers. - July 13, 2023 - Cayman Chemical Company

Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”

Paras Biopharma (Biologics CDMO) Finland team is pleased to announce that its extensive efforts have resulted in the successful scale-up, optimization & development of a biologically-active onco-immunology, “peptide FC-fusion” biologic. - July 12, 2023 - Paras Biopharmaceuticals Finland Oy

Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification

Creative Diagnostics has introduced its new qPCR Assay to the research community. - July 07, 2023 - Creative Diagnostics

Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research

Creative Diagnostics has announced the launch of new reagent solutions for herpesvirus research. - July 07, 2023 - Creative Diagnostics

Paras Biopharma (Biologics CDMO) Maximises Recombinant Protein Expression in Microbial Systems – To Facilitate Economical Scale-Up in Production of Biologics

Paras Biopharma (Biologics CDMO) Finland, a leading biopharmaceutical technology development company in the Nordic region, maximises recombinant protein expression in Microbial Systems in its fully-equipped biologics production facility in Finland. - July 04, 2023 - Paras Biopharmaceuticals Finland Oy

NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial

NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it enrolled and treated the first subject in the Phase IIb RESTORE Trial for newly-diagnosed glioblastoma multiforme... - June 09, 2023 - NuvOx Therapeutics

Creative Diagnostics Announces the Launch of Radial Immunodiffusion Testing Service

Creative Diagnostics has launched its new Single Radial Immunodiffusion Testing services for the biological industry. - June 09, 2023 - Creative Diagnostics

Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases

Creative Diagnostics has launched a set of highly specific antibodies against FXIIIa/F13A1 for vascular diseases. - June 09, 2023 - Creative Diagnostics

New Research Benchmarks Biopharmaceutical Perceptions of Global CRO Thought Leadership

Landmark Research Analyzes Perspectives of US and EU Biopharma C-Suite, Clinical Operations and Medical/Regulatory Affairs Professionals on Global CRO Thought Leadership. - June 01, 2023 - Life Science Strategy Group, LLC

Huntington Study Group Announces Call for Abstracts for 30th Annual Meeting

The Huntington Study Group (HSG), with a mission of accelerating treatments that make a difference for those impacted by Huntington’s disease, together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease... - June 01, 2023 - Huntington Study Group

Creative Diagnostics Announces Calprotectin Reagents for Inflammatory Disease Research

Creative Diagnostics, a leading global supplier of raw materials, antibodies, and reagents to the biotechnology industry, is proud to announce the launch of its new line of Calprotectin Reagents for the study of inflammation disease. Calprotectin is an abundant inflammatory marker in the... - May 20, 2023 - Creative Diagnostics

Creative Diagnostics Introduces Viral Replicon Assay Service to Support Virology Research

Creative Diagnostics recently introduced a series of Viral Replicon Assay services to assist researchers in identifying and studying viruses. - May 20, 2023 - Creative Diagnostics

The Inc. Magazine, USA Includes Paras Biopharma (Biologics CDMO) as One of the Top 10 Most Innovative Biotech Companies to Follow in 2023

Paras Biopharma (Biologics CDMO), a biopharmaceutical technology development company is pleased to be included by The Inc. Magazine, USA as “One of the Top 10 Most Innovative Biotech Companies to Follow in 2023.” The Inc. Magazine serves as an online "go-to" informative tool for business leaders and entrepreneurs, including CEOs and owners of small-to-midsize companies to success, providing news, advice, and inspirational articles. - May 19, 2023 - Paras Biopharmaceuticals Finland Oy

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology. - Statistically Significant Improvement in Chorea Associated with Huntington’s Disease... - May 19, 2023 - Huntington Study Group

Huntington Study Group Achieves Last Patient Last Visit for Its Observational Study to Test Virtual Use of the Unified Huntington’s Disease Rating Scale®

The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., announces an important milestone in the novel observational study Virtual Unified Huntington’s Disease Rating Scale (vUHDRS™). The last participant completed the last visit, marking... - May 16, 2023 - Huntington Study Group

Parvus Therapeutics Announces a Publication Describing the Cellular Origin of Treg Cells Generated Endogenously by Navacim Therapy

Parvus Therapeutics announced today the publication of data showing that peptide-MHC class II-coated nanoparticles (Navacims) operate by triggering the expansion of cognate T follicular helper (TFH) cells. - May 09, 2023 - Parvus Therapeutics U.S., Inc.

New Traceable Opioid Material® Kit Expands Coverage to Other Emerging Drugs of Concern in Seized Samples and Toxicological Casework

Cayman Chemical and the Centers for Disease Control and Prevention (CDC) have released a new addition to the Traceable Opioid Material® Kits (TOM Kits®) product line that expands testing laboratory capabilities beyond synthetic opioids to include additional emerging drugs of abuse that are commonly found as co-drugs in fentanyl-containing samples. - April 30, 2023 - Cayman Chemical Company

Creative Diagnostics Introduces New Low Endotoxin Antibodies for Researchers

Creative Diagnostics recently introduced a new line of low endotoxin antibodies to biopharmaceutical research laboratories. - April 29, 2023 - Creative Diagnostics

Creative Diagnostics Introduces Virus Yield Reduction Assay Service

Creative Diagnostics introduced the Virus Yield Reduction Assay Service to support researchers in evaluating the antiviral activity of compounds. - April 29, 2023 - Creative Diagnostics

Brain Tumor Investment Fund Names Managing Director

National Brain Tumor Society’s venture philanthropy affiliate appoints industry veteran to lead fund designed to invest in and accelerate development of promising new technologies for patients with brain cancer. - April 26, 2023 - National Brain Tumor Society

NuvOx Receives SPAN Grant

NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion - April 24, 2023 - NuvOx Therapeutics

HSG and HD-CAB Collaborate to Provide Global Patient Advisory Board

The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), recently collaborated with Huntington’s Disease – Community Advisory Board (HD-CAB) to provide a... - March 30, 2023 - Huntington Study Group

New Research on Decentralized Clinical Trial (DCT) Strategies to Boost Patient Diversity

Current and Future Clinical Trial Participants Link Enhanced Diversity and Inclusion of Underrepresented Patient Populations to DCT - March 29, 2023 - Life Science Strategy Group, LLC

World Class Hospitals Join DNA Damage Response Consortium to Bring Forward New Treatments for Adults and Children with Brain Cancer

Researchers from St. Jude Children’s Research Hospital, NYU, UCSF, and the University of Minnesota join National Brain Tumor Society and Yale-led Initiative - March 29, 2023 - National Brain Tumor Society

HSG Announces 30th Annual Meeting

The Huntington Study Group (HSG), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently announced that their 2023 Annual Meeting will be held November 2-4, 2023 at the Sheraton Grand at Wild Horse Pass in Chandler, AZ, a... - March 21, 2023 - Huntington Study Group

New Research Identifies Latest Clinical Development and CRO Outsourcing Trends in China

Groundbreaking Research Explores the Chinese Innovative Biopharmaceutical Clinical Development Market, CRO Outsourcing and Future Growth with Over 100 Chinese Biopharma Professionals - March 15, 2023 - Life Science Strategy Group, LLC

Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection

Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera. - March 12, 2023 - Creative Diagnostics

Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research

Creative Diagnostics recently introduced comprehensive contract ELISA kit development services to the R&D and IVD communities. - March 12, 2023 - Creative Diagnostics

NuvOx Newly Issued US Patent

NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it has been issued US Patent No. 11,571,467, “Dodecafluoropentane emulsion (DDFPe) as a stroke and ischemia... - March 02, 2023 - NuvOx Therapeutics

Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers

Creative Diagnostics recently introduced the TCID50 Assay Service suitable for drug sensitivity tests, infectious units quantification, the determination of virus doses, as well as virus release studies. - February 17, 2023 - Creative Diagnostics

Creative Diagnostics Launches HPV L1 Antibodies for Neutralization and Vaccine Development

Creative Diagnostics recently introduced a series of HPV vaccine development products. - February 17, 2023 - Creative Diagnostics

Genesis AEC Celebrates 25th Anniversary

Leading AEC firm’s milestone includes 8,300+ projects for 600+ life sciences leaders nationwide. - January 18, 2023 - Genesis AEC

Huntington Study Group Names First Chief Innovation Officer

The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, today announced Brett Kinsler has been named to the newly created position of Chief Innovation Officer (CINO). - January 10, 2023 - Huntington Study Group

Recent Headlines Within Biopharmaceuticals & Biotherapeutics

Recent Headlines
Within Biopharmaceuticals & Biotherapeutics